Search Results 311-320 of 24197 for In situ

1. BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients - Mayo Clinic

   ... in combination with gemcitabine in advanced pancreatic cancer patients as ... situ (DCIS), or carcinoma in situ of the cervix) unless documented free ...

2. Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery - Mayo Clinic

   EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix. Failure to recover from prior side effects of immune checkpoint inhibitor therapy ...

3. A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ - Mayo Clinic

   ... in treating patients with HER2 expressing ductal carcinoma in situ. H2NVAC is a vaccine designed to stimulate specialized white blood cells in hopes of ...

4. Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer - Mayo Clinic

   EXCEPTIONS: adequately treated non-melanotic skin cancer (adequate wound healing is required prior to study entry) or carcinoma-in-situ of the cervix;; NOTE ...

5. Cores - Mayo Clinic Research

   ... in breast cancer. ... This registry provides SPORE researchers access to diagnostic, treatment and outcome data of well-defined cohorts of patients with in situ ...

6. An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer - Mayo Clinic

   Subjects with carcinoma in situ in surgical margins are not eligible for study entry. All subjects must have pathologic evidence of urothelial carcinoma ...

7. A Study to See if Genetic Risk Estimation of Breast Cancer Influences the Use of Preventive Medication - Mayo Clinic

   Prior history of invasive breast cancer or ductal carcinoma in situ; At risk due to prior radiation therapy to the chest. Participating Mayo Clinic locations.

8. A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) - Mayo Clinic

   Evidence of morphological relapsed, progressive, persistent, or untreated malignancy, with the exception of nonmelanoma skin cancer and in situ ductal carcinoma ...

9. Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma - Mayo Clinic

   ... in-situ of the breast or cervix. NOTE: If there is a history or prior malignancy, patients must not be receiving other specific treatment for their cancer

10. Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer - Mayo Clinic

    ... in situ carcinoma of the cervix are eligible. Subjects with second malignancies that are indolent or definitively treated may be enrolled even if less than ...